Venetoclax for the treatment of translocation (11;14) AL amyloidosis

M. Hasib Sidiqi; Abdullah S. Al Saleh; Nelson Leung; Dragan Jevremovic; Mohammed A. Aljama; Wilson I. Gonsalves; Francis K. Buadi; Taxiarchis V. Kourelis; Rahma Warsame; Eli Muchtar; Miriam A. Hobbs; Martha Q. Lacy; David Dingli; Ronald S. Go; Suzanne R. Hayman; S. Vincent Rajkumar; Angela Dispenzieri; Morie A. Gertz; Shaji K. Kumar; Rafael Fonseca; Prashant Kapoor

doi:10.1038/s41408-020-0321-6

Venetoclax for the treatment of translocation (11;14) AL amyloidosis

M. Hasib Sidiqi, Abdullah S. Al Saleh, Nelson Leung, Dragan Jevremovic, Mohammed A. Aljama, Wilson I. Gonsalves, Francis K. Buadi, Taxiarchis V. Kourelis, Rahma Warsame, Eli Muchtar, Miriam A. Hobbs, Martha Q. Lacy, David Dingli, Ronald S. Go, Suzanne R. Hayman, S. Vincent Rajkumar, Angela Dispenzieri, Morie A. Gertz, Shaji K. Kumar, Rafael FonsecaPrashant Kapoor

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Original language	English (US)
Article number	55
Journal	Blood cancer journal
Volume	10
Issue number	5
DOIs	https://doi.org/10.1038/s41408-020-0321-6
State	Published - May 1 2020

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-020-0321-6

Cite this

Sidiqi, M. H., Al Saleh, A. S., Leung, N., Jevremovic, D., Aljama, M. A., Gonsalves, W. I., Buadi, F. K., Kourelis, T. V., Warsame, R., Muchtar, E., Hobbs, M. A., Lacy, M. Q., Dingli, D., Go, R. S., Hayman, S. R., Rajkumar, S. V., Dispenzieri, A., Gertz, M. A., Kumar, S. K., ... Kapoor, P. (2020). Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood cancer journal, 10(5), Article 55. https://doi.org/10.1038/s41408-020-0321-6

Sidiqi, MH, Al Saleh, AS, Leung, N, Jevremovic, D, Aljama, MA, Gonsalves, WI, Buadi, FK, Kourelis, TV, Warsame, R, Muchtar, E, Hobbs, MA, Lacy, MQ , Dingli, D, Go, RS, Hayman, SR, Rajkumar, SV , Dispenzieri, A , Gertz, MA , Kumar, SK , Fonseca, R & Kapoor, P 2020, 'Venetoclax for the treatment of translocation (11;14) AL amyloidosis', Blood cancer journal, vol. 10, no. 5, 55. https://doi.org/10.1038/s41408-020-0321-6

@article{81201d4ba7564c758214ecf8aeb9790c,

title = "Venetoclax for the treatment of translocation (11;14) AL amyloidosis",

author = "Sidiqi, {M. Hasib} and {Al Saleh}, {Abdullah S.} and Nelson Leung and Dragan Jevremovic and Aljama, {Mohammed A.} and Gonsalves, {Wilson I.} and Buadi, {Francis K.} and Kourelis, {Taxiarchis V.} and Rahma Warsame and Eli Muchtar and Hobbs, {Miriam A.} and Lacy, {Martha Q.} and David Dingli and Go, {Ronald S.} and Hayman, {Suzanne R.} and Rajkumar, {S. Vincent} and Angela Dispenzieri and Gertz, {Morie A.} and Kumar, {Shaji K.} and Rafael Fonseca and Prashant Kapoor",

note = "Funding Information: M.H.S., A.S.A., D.J., M.A.A., T.V.K., R.W., E.M., M.A.H., R.S.G., S.R.H., S.V.R., N.L., W.I.G., F.K.B.: none. M.A.G.: consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis); M.Q.L.: research funding (Celgene); D.D.: research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); S.K.K.: consultancy (Celgene, Millennium, Onyx, Janssen, and BMS), and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). A.D.: research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). R.F.: stock and other ownership interests: Adaptive Biotechnologies; Honoraria: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi; consulting or advisory role: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, AbbVie, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Aduro Biotech, Sanofi; patents, royalties, other intellectual property: patent for the prognostication of multiple myeloma based on genetic categorization of the disease. Travel, accommodations, expenses: multiple. P.K.: research funding (Takeda, Sanofi, AbbVie and Amgen).",

year = "2020",

month = may,

day = "1",

doi = "10.1038/s41408-020-0321-6",

language = "English (US)",

volume = "10",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Venetoclax for the treatment of translocation (11;14) AL amyloidosis

AU - Sidiqi, M. Hasib

AU - Al Saleh, Abdullah S.

AU - Leung, Nelson

AU - Jevremovic, Dragan

AU - Aljama, Mohammed A.

AU - Gonsalves, Wilson I.

AU - Buadi, Francis K.

AU - Kourelis, Taxiarchis V.

AU - Warsame, Rahma

AU - Muchtar, Eli

AU - Hobbs, Miriam A.

AU - Lacy, Martha Q.

AU - Dingli, David

AU - Go, Ronald S.

AU - Hayman, Suzanne R.

AU - Rajkumar, S. Vincent

AU - Dispenzieri, Angela

AU - Gertz, Morie A.

AU - Kumar, Shaji K.

AU - Fonseca, Rafael

AU - Kapoor, Prashant

N1 - Funding Information: M.H.S., A.S.A., D.J., M.A.A., T.V.K., R.W., E.M., M.A.H., R.S.G., S.R.H., S.V.R., N.L., W.I.G., F.K.B.: none. M.A.G.: consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis); M.Q.L.: research funding (Celgene); D.D.: research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); S.K.K.: consultancy (Celgene, Millennium, Onyx, Janssen, and BMS), and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). A.D.: research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). R.F.: stock and other ownership interests: Adaptive Biotechnologies; Honoraria: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi; consulting or advisory role: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, AbbVie, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Aduro Biotech, Sanofi; patents, royalties, other intellectual property: patent for the prognostication of multiple myeloma based on genetic categorization of the disease. Travel, accommodations, expenses: multiple. P.K.: research funding (Takeda, Sanofi, AbbVie and Amgen).

PY - 2020/5/1

Y1 - 2020/5/1

UR - http://www.scopus.com/inward/record.url?scp=85084458725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084458725&partnerID=8YFLogxK

U2 - 10.1038/s41408-020-0321-6

DO - 10.1038/s41408-020-0321-6

M3 - Letter

C2 - 32393733

AN - SCOPUS:85084458725

SN - 2044-5385

VL - 10

JO - Blood cancer journal

JF - Blood cancer journal

IS - 5

M1 - 55

ER -

Venetoclax for the treatment of translocation (11;14) AL amyloidosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this